Halozyme Therapeutics, Inc. focuses on developing drug delivery technologies and therapeutic options to improve patient experiences. Its ENHANZE® drug delivery technology, based on the proprietary enzyme rHuPH20, facilitates subcutaneous delivery of injected drugs, potentially reducing treatment times. The company also markets two FDA-approved products, HYLENEX® and XYOSTED®, and offers custom-designed auto-injectors for subcutaneous and intramuscular use. Halozyme operates primarily in the biopharmaceutical sector, serving partners and patients in various therapeutic areas.
